FENG Ting, QU Ying, LIU Lian, WANG Lin. Incidence and severity grading of treatment-related adverse event associated with programmed death-1/programmeddeath-ligand 1 inhibitors combined with various anticancer regimens[J]. Journal of Clinical Medicine in Practice, 2025, 29(2): 19-23. DOI: 10.7619/jcmp.20244644
Citation: FENG Ting, QU Ying, LIU Lian, WANG Lin. Incidence and severity grading of treatment-related adverse event associated with programmed death-1/programmeddeath-ligand 1 inhibitors combined with various anticancer regimens[J]. Journal of Clinical Medicine in Practice, 2025, 29(2): 19-23. DOI: 10.7619/jcmp.20244644

Incidence and severity grading of treatment-related adverse event associated with programmed death-1/programmeddeath-ligand 1 inhibitors combined with various anticancer regimens

More Information
  • Received Date: October 07, 2024
  • Revised Date: December 16, 2024
  • Objective 

    To analyze the incidence and severity grading of treatment-related adverse event (TRAE) associated with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors combined with various anticancer regimens.

    Methods 

    A total of 356 tumor patients treated with PD-1/PD-L1 inhibitors were retrospectively selected as the study objects. The occurrence of adverse reactions in patients treated with PD-1/PD-L1 inhibitors combined with different anticancer regimens was recorded and analyzed.

    Results 

    Among the 356 patients treated with PD-1/PD-L1 inhibitors in combination with various anticancer regimens, 332 times of TRAEs were observed. Fatigue and adverse gastrointestinal reactions were the most prevalent, accounting for 31.93% (106/332) and 20.78% (69/332) respectively. Skin-related adverse reactions (appearing within 3 to12 weeks) and gastrointestinal adverse reactions (5 to 10 weeks) occurred first, while fever (10 to 30 weeks) and pneumonia (12 to 32 weeks) presented later, with the longest observation time span. The lowest overall incidence of TRAE was observed in the combination of PD-1/PD-L1 inhibitors with cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors (85.71%, 36/42), while the highest was in the combination with platinum-based doublet chemotherapy (96.88%, 155/160). The incidence of grade 3 to 5 TRAEwas lowest in the combination of PD-1/PD-L1 inhibitors with radiotherapy (10.53%, 6/57) and highest in the combination with vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) targeted therapy (44.64%, 25/56). There was no significant difference in the incidence and severity of TRAE among different tumors (P>0.05).

    Conclusion 

    When different anti-cancer regiments combined with PD-1/PD-L1 inhibitors, the overall incidence of TRAE is higher, among which the incidence of TRAE combined with CTLA-4 is relatively lowest, and the symptoms of TRAE combined with radiotherapy are relatively mild.

  • [1]
    CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7): 783-791. doi: 10.1097/CM9.0000000000001474
    [2]
    SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
    [3]
    LI C M, HARATIPOUR P, LINGEMAN R G, et al. Novel peptide therapeutic approaches for cancer treatment[J]. Cells, 2021, 10(11): 2908. doi: 10.3390/cells10112908
    [4]
    PATEL S A, NILSSON M B, LE X N, et al. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy[J]. Clin Cancer Res, 2023, 29(1): 30-39. doi: 10.1158/1078-0432.CCR-22-1366
    [5]
    WU Q, QIAN W, SUN X L, et al. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021[J]. J Hematol Oncol, 2022, 15(1): 143. doi: 10.1186/s13045-022-01362-9
    [6]
    FREITES-MARTINEZ A, SANTANA N, ARIAS-SANTIAGO S, et al. Using the common terminology criteria for adverse events (CTCAE-version 5. 0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr, 2021, 112(1): 90-92. doi: 10.1016/j.ad.2019.05.009
    [7]
    LUO F R, DING J, CHEN H X, et al. Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting[J]. Chin J Cancer, 2014, 33(12): 620-624.
    [8]
    MAGGIORE U, PALMISANO A, BUTI S, et al. Chemotherapy, targeted therapy and immunotherapy: which drugs can be safely used in the solid organ transplant recipients?[J]. Transpl Int, 2021, 34(12): 2442-2458. doi: 10.1111/tri.14115
    [9]
    YI M, ZHENG X L, NIU M K, et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions[J]. Mol Cancer, 2022, 21(1): 28. doi: 10.1186/s12943-021-01489-2
    [10]
    CHEN Y X, LIU Y Z, WANG Y, et al. Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages[J]. J Exp Clin Cancer Res, 2022, 41(1): 1. doi: 10.1186/s13046-021-02201-4
    [11]
    孙颖丽, 刘一, 任晓蕾, 等. 信迪利单抗治疗胃癌致甲状腺免疫相关不良反应的单中心回顾性研究[J]. 临床药物治疗杂志, 2024, 22(3): 38-42.
    [12]
    周潇翔. 抗PD-1/PD-L1免疫治疗的不良反应谱及其预测标志物探究[D]. 北京: 北京协和医学院, 2021.
    [13]
    RAMOS-CASALS M, BRAHMER J R, CALLAHAN M K, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020, 6(1): 38.
    [14]
    SCHACHTER J, RIBAS A, LONG G V, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)[J]. Lancet, 2017, 390(10105): 1853-1862. doi: 10.1016/S0140-6736(17)31601-X
    [15]
    ZHANG H, DAI Z Y, WU W T, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 184. doi: 10.1186/s13046-021-01987-7
    [16]
    ALKHOLIFI F K, ALSAFFAR R M. Dostarlimab an inhibitor of PD-1/PD-L1: a new paradigm for the treatment of cancer[J]. Medicina, 2022, 58(11): 1572. doi: 10.3390/medicina58111572
    [17]
    JANJIGIAN Y Y, SHITARA K, MOEHLER M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40.
    [18]
    LI C H, WANG L X, SUN D Q, et al. Colitis induced by PD-1 inhibitor combined with platinum-containing dual drug chemotherapy in Lewis mice and its mechanism[J]. J Cancer Res Ther, 2023, 19(4): 939-944.
    [19]
    MOTZER R, ALEKSEEV B, RHA S Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma[J]. N Engl J Med, 2021, 384(14): 1289-1300.
    [20]
    梁万霞, 赵宇, 廖金花, 等. 信迪利单抗联合阿帕替尼对比阿帕替尼二线治疗晚期食管癌的疗效及安全性[J]. 安徽医学, 2021, 42(5): 530-533.
    [21]
    ZHAO Y S, GUO S P, DENG J, et al. VEGF/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment[J]. Int J Biol Sci, 2022, 18(9): 3845-3858.
    [22]
    李加兵, 汤召兵. 基于程序性死亡受体1/程序性死亡受体配体1抑制剂的免疫治疗在晚期肾细胞癌中的研究进展[J]. 癌症进展, 2022, 20(8): 760-765.
  • Related Articles

    [1]WU Tingjiang. Comparison of effect of different surgery timing after hip fracture in elderly patients[J]. Journal of Clinical Medicine in Practice, 2020, 24(16): 85-87,91. DOI: 10.7619/jcmp.202016024
    [2]LIU Changzhi. Interlocking intramedullary nail versus minimally invasive percutaneous plate internal fixation in the treatment of middle or lower tibial fractures[J]. Journal of Clinical Medicine in Practice, 2019, 23(22): 43-45, 48. DOI: 10.7619/jcmp.201922015
    [3]ZHANG Huiqing, WANG Yarong. Rehabilitation nursing for patients with fractures in radius and ulna[J]. Journal of Clinical Medicine in Practice, 2019, 23(13): 109-111, 119. DOI: 10.7619/jcmp.201913031
    [4]YU Huamei, TIAN Haizhen, QIN Limin, SU Yujin. Effect of nursing intervention in operation room on incision healing and complications in patients with gastrointestinal surgery[J]. Journal of Clinical Medicine in Practice, 2016, (18): 111-113. DOI: 10.7619/jcmp.201618036
    [5]QIN Qiong. Complications analysis and nursing countermeasures in patients with limb fractures during bedridden time[J]. Journal of Clinical Medicine in Practice, 2015, (14): 81-83. DOI: 10.7619/jcmp.201514026
    [6]SHANG Bo. Relationship between postoperative complications of soft tissue and different operation time of incision reduction combined with internal fixation operation in patients with calcaneus fracture[J]. Journal of Clinical Medicine in Practice, 2014, (19): 66-69. DOI: 10.7619/jcmp.201419020
    [7]ZHAO Xuehong. Analysis of prospective nursing on the functional recovery and complications in patients with lower limb fracture[J]. Journal of Clinical Medicine in Practice, 2014, (10): 111-112,115. DOI: 10.7619/jcmp.201410040
    [8]WU Xiaoli, WANG Fang, JI Jianhong. Influence of gastric lavage monitoring system for detecting liquid input-output balance on complications of gastric lavage[J]. Journal of Clinical Medicine in Practice, 2013, (20): 85-87. DOI: 10.7619/jcmp.201320029
    [9]ZHUANG Zhaorong, YIN Daju. Nursing for gastric cancer patients with early postoperative complications[J]. Journal of Clinical Medicine in Practice, 2013, (12): 14-16,19. DOI: 10.7619/jcmp.201312006
    [10]CHEN Yunlan, QIU Meiling. Nursing for postoperative complications in patients with hysterectomy[J]. Journal of Clinical Medicine in Practice, 2013, (10): 95-97. DOI: 10.7619/jcmp.201310035
  • Cited by

    Periodical cited type(5)

    1. 汤思,陈学杰. 直接抗人球蛋白试验阳性分型与输血疗效的相关性. 吉林医学. 2024(02): 295-297 .
    2. 杨占甲,李丽娟,宋银森. 多发性骨髓瘤患者红细胞输注效果的影响因素探讨. 中国实用医刊. 2024(13): 66-69 .
    3. 梁冬香,钟昌瑞,傅春花,邱启东. 直接抗人球蛋白试验凝集强度的结果分析及临床意义. 临床血液学杂志. 2024(12): 905-908 .
    4. 闻才李,张慧,杨吉岳,孙一心,程晓文. 直接抗人球蛋白试验阳性患者298例的病因回顾性分析. 医药论坛杂志. 2022(08): 72-74+78 .
    5. 胡泽斌,孙彬裕,孙晶,王布强,于婷. 抗人球蛋白检测卡行业标准的研究. 中国医药生物技术. 2022(05): 449-452 .

    Other cited types(0)

Catalog

    Article views PDF downloads Cited by(5)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return